1Tutrone WD, Kagen MH, Barbagallo J, et al. Biologic therapy for psoriasis: a brief history, Ⅰ. Cutis, 2001, 68(5) :331-336.
2Tutrone WD, Kagen MH, Barbagallo J, et al. Biologic therapy for psoriasis: a brief history, Ⅱ. Cutis, 2001, 68(6) :367-372.
3Gottlieb AB. Psoriasis. Immunopathology and immunomodulation.Dermatol Clin, 2001, 19(4) :649-657.
4Papp K, Bissonnette R, Krueger JG, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dennatol, 2001,45 ( 5 ) :665-674.
7Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenie mice from cachexia and TNF lethality in vivo [ J ]. Cytokine,1995,7( 1 ) : 15-25.
8Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease[ J]. Lancet, 1993,342 (8864) : 173-174.
9Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents[J]. J Pediatr, 2000, 137(2) :192-196.
10Targan SR, Hanauer SB, vail Deventer S, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease[J]. N Engl J Med, 1997,337(15) : 1029-1035.
